Modulation of hepcidin to treat iron deregulation: potential clinical applications.
Modulation of hepcidin to treat iron deregulation: potential clinical applications.
复制标题
DOI：
10.1586/17474086.2016.1124757
复制
发表时间：
2016
影响因子：
2.8
通讯作者：
Torti SV
中科院分区：
文献类型：
--
作者：
Blanchette NL;Manz DH;Torti FM;Torti SV
分泌的肽激素铁调素通过降解铁输出蛋白膜铁转运蛋白调节全身和局部铁稳态。铁调素的失调导致改变的铁稳态和病理性疾病的发展，包括血色素沉着症、铁负荷和铁限制性贫血。铁调素的治疗性调节是改善这些病症的有前景的方法。已经采取了几种方法来增强或降低铁调素在体外和体内的作用。基于这些方法，已经开发出铁调素调节药物并正在进行临床评价。在这篇文章中，我们回顾了这些药物的发展的基本原理，有关其安全性和有效性的数据，其治疗用途，以及潜在的未来前景。
The secreted peptide hormone hepcidin regulates systemic and local iron homeostasis through degradation of the iron exporter ferroportin. Dysregulation of hepcidin leads to altered iron homeostasis and development of pathological disorders including hemochromatosis, and iron loading and iron restrictive anemias. Therapeutic modulation of hepcidin is a promising method to ameliorate these conditions. Several approaches have been taken to enhance or reduce the effects of hepcidin in vitro and in vivo. Based on these approaches, hepcidin modulating drugs have been developed and are undergoing clinical evaluation. In this article we review the rationale for development of these drugs, the data concerning their safety and efficacy, their therapeutic uses, and potential future prospects.